News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Shankar Siva: OMET trial in oligometastatic HNSCC
Shankar Siva/iconcancercentre.com.au
Mar 28, 2025, 14:03

Shankar Siva: OMET trial in oligometastatic HNSCC

Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X:

“OMET trial (GORTEC 2014-04) in oligometastatic HNSCC.

N=69, SABR alone vs SABR + chemo + cetuximab.

Key finding:

  • Similar 1-year OS without QoL (SABR 55.2% vs chemo-SABR 53.3%).
  • SABR alone had toxicity and QoL impact.
  • Gr 3–4 tox: 8.8% (SABR alone) vs 60%.

Shankar Siva: OMET trial in oligometastatic HNSCC

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Authors: Juliette Thariat, et al.

Shankar Siva: OMET trial in oligometastatic HNSCC

Phase II randomized design:

  • 1–3 oligometastases, mostly lung.
  • Median OS ~42 mo both arms.
  • QoL deterioration (median drop):

– SABR: 16.7 patients.

– Chemo-SABR: 50 patients.

QoL assessed with EORTC QLQ-C30.”

Shankar Siva: OMET trial in oligometastatic HNSCC

Toxicity snapshot:

Grade ≥3 toxicity:

  • 60% with chemo vs 8.8% with SABR-only.
  • No grade 5 events.
  • Chemo toxicities: anemia, nausea, mucositis, hypomagnesemia, etc.

QoL declines closely linked to non-haem grade ≥3 toxicities.”

Bottom line for clinicians:

In select patients with oligometastatic HNSCC, SABR alone offers comparable survival with toxicity and better QoL.

Repeated SABR feasible at relapse SABR-only arm also shown to be cost-efficient.

Full paper.

Sue Yom–ASTRO upcoming podcast for APRIL 2025.”

anemia ASTRO cancer cetuximab chemotherapy EORTC fight against cancer Global fight against cancer GORTEC Head and Neck Cancer HNSCC hypomagnesemia Juliette Thariat mucositis nausea Oligometastases OMET OncoDaily Oncology Peter MacCallum Cancer Centre quality of life RadOnc SABR Shankar Siva Stereotactic Ablative Radiation Therapy Sue Yom
Special Coverage
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC
Blog
Mar 30, 2025, 16:43
Highlights from SSO25
Blog
Mar 30, 2025, 16:38
Embracing Palliative Care in Paediatric Oncology from Diagnosis Onwards course is now available on YouTube - SIOPE
Blog
Mar 30, 2025, 16:09
Hedley Lewis: No Family Should Face Childhood Cancer and Life-Threatening Blood Disorders Alone
Blog
Mar 30, 2025, 16:06
Anant Madabhushi: New Publication on AI-Driven Virtual Staining for Tumor-Associated Macrophages
Blog
Mar 30, 2025, 16:03
Research drives progress, and advocacy fuels change - Fight Colorectal Cancer
Blog
Mar 30, 2025, 15:52
St. Baldrick's Foundation - Honoring our heroes on National Doctors' Day
Blog
Mar 30, 2025, 15:48
Our experts are in Orlando for NCCN2025 - Roswell Park
Blog
Mar 30, 2025, 15:42
Peter Pisters: Honoring MD Anderson Cancer Center's Physicians on Doctors' Day for their commitment
Blog
Mar 30, 2025, 15:41
New NCI Funding Opportunity to New NCI Funding Opportunity to Address Cancer-Related Financial Hardship to Improve Patient Outcomes